Tuesday, October 29, 2019 Daily Archives

Single-Use Technologies: Accelerating Bioprocess Design with Key Insights from the Experts

by

Companies turn more and more to single-use technologies (SUTs) to mitigate production challenges — and with good reason. SUTs clearly decrease conventional costs while increasing process integrity. Yet as the writers in this compilation suggest, SUTs are now making possible new, exciting ways to configure, operate, and evaluate biomanufacturing. In this compilation, BioProcess International gathers key insights from biopharmaceutical industry experts at Sartorius Stedim Biotech to explore how SUTs can realize high-quality yet cost-effective end-to-end bioprocessing. The studies herein identify…

October 29, 2019

Bio-Techne confirms $50m reagents plant to support CGTs

by

Bio-Techne will build a 50,000 square-foot plant in Minnesota with an initial capacity of $140 million of E. coli-derived recombinant proteins to support cell and gene therapy developers. After months of talk, life sciences services and consumables firm Bio-Techne has laid concrete plans to build a facility in St Paul, Minnesota to produce GMP reagent proteins for use in cell and gene therapy applications. “The facility is expected to go through qualifications in approximately one year, with commercial sales expected…

October 29, 2019

Supplier relationships critical in driving process intensification, says BMS

by

Process intensification is driving down costs in the biologics space, but manufacturing firms need to treat vendors like partners and not simply suppliers, says Bristol-Myers Squibb. Process intensification emerged as one of the hot topics at Biotech Week Boston last month. There were multiple talks and discussions looking at strategies such as perfusion-based cell culture, multicolumn chromatography in the downstream, and the increased use of analytical technologies aimed at intensifying manufacturing processes. Ciaran Brady, executive director of Manufacturing, Science and…

October 29, 2019

Thermo Fisher: ‘Bio market is good but our position is better’

by

Thermo Fisher has reported another quarter of double-digit in its life sciences division attributing its competitive strength to its diversified offering. For the third quarter 2019, Thermo Fisher reported sales of $6.3 billion (€5.7 billion), up 6% year-on-year. Within the firm’s Life Sciences Solutions Segment division, which includes bioprocess equipment and its biomanufacturing business, revenues grew 13% to $1.7 billion. Last quarter, analysts claimed the “bioprocessing ecosystem [was] on fire,†and another period of double-digit growth, for Thermo Fisher at…

October 29, 2019